Skip to content

Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer

Cancer Information Service Research Consortium: Years 2006-2011 Program Narrative and Overview

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00830635
Enrollment
1800
Registered
2009-01-28
Start date
2008-09-30
Completion date
2013-12-31
Last updated
2015-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Depression, Long-term Effects of Cancer Treatment, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment

Keywords

long-term effects of cancer treatment, psychosocial effects of cancer and its treatment, depression, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage I prostate cancer, stage II prostate cancer

Brief summary

RATIONALE: A multimedia educational program may help patients with newly diagnosed prostate cancer and breast cancer reduce distress, make informed treatment decisions, and improve quality of life. PURPOSE: This randomized clinical trial is studying how well a multimedia educational program works in patients with early-stage prostate cancer or breast cancer.

Detailed description

OBJECTIVES: Primary * Determine whether an innovative multimedia educational program will help newly diagnosed prostate (project 1) and breast (project 2) cancer patients prepare for their journey as cancer patients, promote informed treatment decision-making and reduce cancer-specific distress, and among breast cancer patients at re-entry, facilitate an informed re-entry transition to cancer survivorship and reduce cancer-specific distress (project 3). * Determine whether having Cancer Information Service (CIS) Information Specialists make a scheduled telephone callback to callers in project 3 will augment and support use of the CIS Research Consortium (CISRC) multimedia educational programs and further enhance the study outcomes examined in this program of research. * Determine whether the hypothesized mediational variables account for significant intervention effects in each of the three component projects. * Examine potential moderator variables to assess potential differences in intervention efficacy by selected subgroups (e.g., age, education) within each component project. * Conduct an in-depth tracking study of utilization patterns for a detailed description of different patterns of use, as well as elucidating those components or modules within the program that had differential utilization by participants. * Assist the CIS and other similar cancer information systems in disseminating one or more of the CISRC interventions should they prove effective in this program of research. Secondary * Conduct secondary analyses across projects (i.e., perceived need for and benefit from the CISRC interventions and intervention efficacy across three high priority cancer patient populations) that will be made possible by the use of a common theoretical framework, the same or similar intervention and research design across projects, and a common set of endpoints. OUTLINE: This is a multicenter study. Patients are assessed by demographic questions and a baseline interview conducted by Cancer Information Service (CIS) Information Specialists. Patients are randomized to 1 of 3 intervention groups: * Group 1: Patients receive a mailing containing standard CIS print materials. In project 1, patients receive Treatment Choices for Men with Early-Stage Prostate Cancer and What You Need to Know About Prostate Cancer. In project 2, patients receive What You Need to Know About Breast Cancer and Surgery Choices for Women with Early-Stage Breast Cancer. In project 3, patients receive Facing Forward: Life After Cancer Treatment and What You Need to Know About Breast Cancer. * Group 2: Patients receive mailings appropriate to their project as in group 1. Patients also receive the multimedia program via the Internet or CD-ROM. * Group 3: In project 3 only, patients receive mailings appropriate to their project as in group 1 and the multimedia program as in group 2. Patients also receive a CIS callback intervention at 10-14 days from trained Information Specialists from the CIS. After completion of study therapy, patients are followed at 2 and 9 months.

Interventions

OTHEReducational intervention
OTHERinformational intervention
OTHERinternet-based intervention
OTHERquestionnaire administration
OTHERstudy of socioeconomic and demographic variables
OTHERsurvey administration
PROCEDUREpsychosocial assessment and care
PROCEDUREquality-of-life assessment

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Patients are diagnosed with 1 of the following: * Diagnosis of prostate cancer (project 1) * Early-stage disease * Previously untreated disease or treatment status unknown * Diagnosis of breast cancer (projects 2-3) * Early-stage disease * No ductal carcinoma in situ or lobular carcinoma in situ * Inflammatory breast cancer allowed (project 2) * Previously untreated disease, receiving concurrent treatment, previously treated disease, or treatment status unknown * No more than 30 days since completion of treatment OR no more than 6 months post-treatment (project 3) PATIENT CHARACTERISTICS: * Has access to a computer * Willing to provide mailing address and telephone number * Must be active information-seekers who have already called the CIS * Understands English PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

MeasureTime frame
Physical functioning
Interpersonal functioning
Benefit-finding
Decisional conflict (projects 1 and 2)
Regret (projects 1 and 2)
Fear of recurrence (project 3)
Practical concerns (project 3)
Cancer-specific distress
Emotional quality of life

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026